#TransCode_Therapeutics

@newsen.bsky.social

1 week ago

TransCode's Groundbreaking License Agreement for Innovative Oncolytic Immunotherapy Platform TransCode Therapeutics has secured an exclusive license for next-gen oncolytic immunotherapy, enhancing cancer treatment options. Discover the potential impact on patients!

TransCode's Groundbreaking License Agreement for Innovative Oncolytic Immunotherapy Platform #USA #Boston #Immuno-Oncology #TransCode_Therapeutics #UIO-524

1 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

TransCode Therapeutics Publishes Groundbreaking Research on RIG-I Immunotherapy for Cancer Treatment TransCode Therapeutics published a pivotal study on RIG-I immunotherapy, showcasing its potential in precision cancer treatment and imaging.

TransCode Therapeutics Publishes Groundbreaking Research on RIG-I Immunotherapy for Cancer Treatment #USA #cancer_therapy #Boston #TransCode_Therapeutics #RIG-I_agonist

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

TransCode Therapeutics and Quantum Leap Submit IND Amendment for Phase 2a Trial of TTX-MC138 TransCode Therapeutics in collaboration with Quantum Leap Healthcare has submitted an IND amendment for their Phase 2a clinical trial evaluating TTX-MC138. This step aims to combat advanced colorectal cancer.

TransCode Therapeutics and Quantum Leap Submit IND Amendment for Phase 2a Trial of TTX-MC138 #USA #Boston #TTX-MC138 #TransCode_Therapeutics #Quantum_Leap

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

TransCode Therapeutics Shares Promising Preclinical Findings for TTX-MC138 in Glioblastoma Treatment TransCode Therapeutics has announced key preclinical findings on TTX-MC138, highlighting its potential in treating aggressive glioblastoma and improving patient survival rates.

TransCode Therapeutics Shares Promising Preclinical Findings for TTX-MC138 in Glioblastoma Treatment #USA #Boston #Glioblastoma #TTX-MC138 #TransCode_Therapeutics

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

TransCode Therapeutics Welcomes Jack E. Stover to its Board of Directors TransCode Therapeutics has appointed Jack E. Stover to its Board of Directors, enhancing its strategic leadership in cancer treatment.

TransCode Therapeutics Welcomes Jack E. Stover to its Board of Directors #USA #Boston #TransCode_Therapeutics #RNA #Jack_E._Stover

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

TransCode Therapeutics Unveils Promising Phase 1a Results for TTX-MC138 at ESMO Congress TransCode Therapeutics reported encouraging preliminary data from its Phase 1a trial of TTX-MC138 focusing on metastatic diseases. The trial shows a robust safety profile and promising efficacy.

TransCode Therapeutics Unveils Promising Phase 1a Results for TTX-MC138 at ESMO Congress #USA #Boston #TTX-MC138 #TransCode_Therapeutics #Phase_1a_Trial

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

TransCode Therapeutics Expands Immuno-Oncology Pipeline with Polynoma Acquisition TransCode Therapeutics announced a significant acquisition of Polynoma, enhancing its oncology portfolio with a unique immuno-oncology solution. This transaction includes a $25 million financing to support future advancements.

TransCode Therapeutics Expands Immuno-Oncology Pipeline with Polynoma Acquisition #United_States #San_Diego #TransCode_Therapeutics #Polynoma #CK_Life_Sciences

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

TransCode Therapeutics Approves Reverse Stock Split to Enhance Trading Price on Nasdaq TransCode Therapeutics has announced a reverse stock split of 1-for-28, aimed at increasing its stock price to meet Nasdaq listing requirements. The split takes effect on May 15, 2025.

TransCode Therapeutics Approves Reverse Stock Split to Enhance Trading Price on Nasdaq #United_States #Stock_Split #Boston #TransCode_Therapeutics #RNA_oncology

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Meet Nasdaq Listing Requirements TransCode Therapeutics has announced a reverse stock split of 1-for-28 to comply with Nasdaq's listing requirements and boost share price.

TransCode Therapeutics Implements 1-for-28 Reverse Stock Split to Meet Nasdaq Listing Requirements #USA #NASDAQ #Boston #TransCode_Therapeutics #RNA_Oncology_Company

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

10 months ago

TransCode Therapeutics: Significant Advances in Phase 1a Clinical Trial for Metastatic Cancer Treatment TransCode Therapeutics has reported promising progress in its Phase 1a clinical trial for metastatic cancer, with no significant toxicities observed, showcasing the therapeutic potential of TTX-MC138.

TransCode Therapeutics: Significant Advances in Phase 1a Clinical Trial for Metastatic Cancer Treatment #USA #Boston #TTX-MC138 #TransCode_Therapeutics #metastatic_cancer

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

TransCode Therapeutics Urges Shareholders to Support a Reverse Stock Split Proposal TransCode Therapeutics, Inc. invites shareholders to vote on a pivotal proposal for a reverse stock split, crucial for maintaining NASDAQ compliance.

TransCode Therapeutics Urges Shareholders to Support a Reverse Stock Split Proposal #USA #Boston #Stockholders #Reverse_Stock_Split #TransCode_Therapeutics

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

TransCode Therapeutics Moves Forward with Phase 1 Clinical Trial for TTX-MC138 TransCode Therapeutics has announced the initial dosing of a patient in the fourth cohort of its Phase 1 trial for the TTX-MC138 therapy, aimed at treating metastatic cancer.

TransCode Therapeutics Moves Forward with Phase 1 Clinical Trial for TTX-MC138 #United_States #Boston #RNA_Therapeutics #TTX-MC138 #TransCode_Therapeutics

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

TransCode Therapeutics Completes Direct Stock Offering, Enhancing Funding for Oncology Innovations TransCode Therapeutics has successfully closed a registered direct stock offering, raising $10 million for advancing RNA therapeutic research and development.

TransCode Therapeutics Completes Direct Stock Offering, Enhancing Funding for Oncology Innovations #USA #Boston #RNA_Therapeutics #TTX-MC138 #TransCode_Therapeutics

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

11 months ago

TransCode Therapeutics Launches Direct Offering to Fund Cancer Treatment Development TransCode Therapeutics has announced a direct offering to raise funds for cancer research. The offering is set to close on March 25, 2025.

TransCode Therapeutics Launches Direct Offering to Fund Cancer Treatment Development #United_States #Boston #TTX-MC138 #TransCode_Therapeutics #RNA_oncology

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 year ago